Zidesamtinib (NVL-520)
TKI pre-treated advanced ROS1+ NSCLC
Key Facts
About Nuvalent
Nuvalent leverages deep expertise in chemistry and structure-based drug discovery to create precisely targeted therapies that address the dual challenges of kinase resistance and selectivity in oncology. The company's lead programs include zidesamtinib (NVL-520) for ROS1+ NSCLC with PDUFA target action in 2H 2026, and neladalkib (NVL-655) for ALK+ NSCLC currently in Phase 3 trials. With a robust pipeline targeting validated kinase targets and a strong commercial organization, Nuvalent is positioned to deliver durable responses for cancer patients with limited treatment options.
View full company profileAbout Nuvalent
Nuvalent leverages deep expertise in chemistry and structure-based drug discovery to create precisely targeted therapies that address the dual challenges of kinase resistance and selectivity in oncology. The company's lead programs include zidesamtinib (NVL-520) for ROS1+ NSCLC with PDUFA target action in 2H 2026, and neladalkib (NVL-655) for ALK+ NSCLC currently in Phase 3 trials. With a robust pipeline targeting validated kinase targets and a strong commercial organization, Nuvalent is positioned to deliver durable responses for cancer patients with limited treatment options.
View full company profileAbout Nuvalent
Nuvalent leverages deep expertise in chemistry and structure-based drug discovery to create precisely targeted therapies that address the dual challenges of kinase resistance and selectivity in oncology. The company's lead programs include zidesamtinib (NVL-520) for ROS1+ NSCLC with PDUFA target action in 2H 2026, and neladalkib (NVL-655) for ALK+ NSCLC currently in Phase 3 trials. With a robust pipeline targeting validated kinase targets and a strong commercial organization, Nuvalent is positioned to deliver durable responses for cancer patients with limited treatment options.
View full company profile